These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 8849078)
21. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077 [TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. Papp KA; Breuer K; Meurer M; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C J Am Acad Dermatol; 2005 Feb; 52(2):247-53. PubMed ID: 15692469 [TBL] [Abstract][Full Text] [Related]
23. [Vaccine coverage and levels of protection with triple viral vaccine in a children population]. Sánchez Serrano LP; Corcuera MT; Molina MP; de Miguel C; Lozano J; Oñorbe JA; Barberá G Enferm Infecc Microbiol Clin; 1990; 8(6):384-7. PubMed ID: 2081176 [TBL] [Abstract][Full Text] [Related]
25. A search for persistent measles, mumps, and rubella vaccine virus in children with human immunodeficiency virus type 1 infection. Frenkel LM; Nielsen K; Garakian A; Cherry JD Arch Pediatr Adolesc Med; 1994 Jan; 148(1):57-60. PubMed ID: 8143011 [TBL] [Abstract][Full Text] [Related]
26. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia. Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396 [TBL] [Abstract][Full Text] [Related]
27. Immune responses to measles immunization and the impacts on HIV-infected children. Thaithumyanon P; Punnahitananda S; Thisyakorn U; Praisuwanna P; Ruxrungtham K Southeast Asian J Trop Med Public Health; 2000 Dec; 31(4):658-62. PubMed ID: 11414407 [TBL] [Abstract][Full Text] [Related]
28. [Changes in measles, mumps and rubella (MMR) immunity until the year of 2002 after the introduction of MMR vaccination]. Rønne T; Trier H Ugeskr Laeger; 1992 Jul; 154(29):2014-8. PubMed ID: 1509567 [TBL] [Abstract][Full Text] [Related]
29. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100 [TBL] [Abstract][Full Text] [Related]
30. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age. Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985 [TBL] [Abstract][Full Text] [Related]
31. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella]. Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398 [TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related]
33. Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid. Barbi M; Biffi MR; Binda S; Clerici-Schoeller M; Ferraris G; Luraschi C; Masella P; Mazzoni P; Pozzi A; Pregliasco F AIDS; 1992 Dec; 6(12):1465-9. PubMed ID: 1492931 [TBL] [Abstract][Full Text] [Related]
34. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia. Feldman S; Andrew M; Norris M; McIntyre B; Iyer R Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893 [TBL] [Abstract][Full Text] [Related]
35. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection. Cilla G; Peña B; Marimón JM; Pérez-Trallero E Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345 [TBL] [Abstract][Full Text] [Related]
36. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection. Ratnam S; West R; Gadag V J Pediatr; 1995 Sep; 127(3):432-4. PubMed ID: 7658276 [TBL] [Abstract][Full Text] [Related]
37. [The clinico-immunological evaluation of a bivalent vaccine against measles and rubella]. Schettini F; Manzionna MM; De Mattia D; Amendola F; Di Bitonto G Minerva Pediatr; 1990 Dec; 42(12):531-6. PubMed ID: 2087226 [TBL] [Abstract][Full Text] [Related]
38. Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine. Giammanco G; Li Volti S; Salemi I; Giammanco Bilancia G; Mauro L Eur J Epidemiol; 1993 Mar; 9(2):199-202. PubMed ID: 8519358 [TBL] [Abstract][Full Text] [Related]
39. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. Arpadi SM; Markowitz LE; Baughman AL; Shah K; Adam H; Wiznia A; Lambert G; Dobroszycki J; Heath JL; Bellini WJ Pediatrics; 1996 May; 97(5):653-7. PubMed ID: 8628602 [TBL] [Abstract][Full Text] [Related]
40. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy. Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]